Intuitive Surgical 과거 순이익 실적
과거 기준 점검 4/6
Intuitive Surgical은 연평균 16.7%의 비율로 수입이 증가해 온 반면, Medical Equipment 산업은 수입이 15.3% 증가했습니다. 매출은 연평균 14.7%의 비율로 증가했습니다. Intuitive Surgical의 자기자본이익률은 17.3%이고 순이익률은 28.4%입니다.
핵심 정보
16.72%
순이익 성장률
16.64%
주당순이익(EPS) 성장률
| Medical Equipment 산업 성장률 | 8.90% |
| 매출 성장률 | 14.68% |
| 자기자본이익률 | 17.26% |
| 순이익률 | 28.45% |
| 최근 순이익 업데이트 | 30 Jun 2026 |
최근 과거 실적 업데이트
Recent updates
Seeking Alpha • Aug 12
Intuitive Surgical: Priced For Precision
Summary Intuitive Surgical is rated a Hold, with a modeled +9.17% upside and a price target of $426.65. ISRG's growth thesis centers on untapped ASC procedure volume, overstated remanufacturing risks, and remanufacturing's role in expanding the installed base. Remanufacturing currently poses a limited threat, with sub-3% penetration and approval for only 4 out of 45+ instruments. ISRG trades at a premium (30.5x EV/EBITDA, 44x P/E) due to high growth (19% Y/Y) and 85% recurring revenue. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 04
ISRG: Slowing U.S. Procedures And ACA Risks Will Pressure Rich Expectations
The updated analyst price target for Intuitive Surgical moves from about $412 to $324. This reflects lower implied revenue growth and P/E assumptions, even as analysts highlight healthy procedure trends, strong profitability, and ongoing questions around U.S. procedure momentum, automation driven adoption, and Affordable Care Act related procedure risks.
내러티브 업데이트 • Jul 21
ISRG: Future Returns Will Rely On Procedure Utilization Outpacing Medtech Sector Rotation
Intuitive Surgical's updated analyst price target reflects a reset from $565.25 to $501.73, as analysts factor in slightly softer procedure growth expectations, modestly adjusted revenue growth assumptions, and a lower applied future P/E multiple despite stable to slightly higher modeled profit margins. Analyst Commentary Recent Street research on Intuitive Surgical points to a reset in expectations rather than a collapse in confidence.
내러티브 업데이트 • Jul 07
ISRG: Procedure Momentum And Sector Reset Will Drive 2026 Upside
Intuitive Surgical's analyst price target has been reduced by $32.56 to $717.44 as analysts temper fair value, revenue growth, and margin assumptions in light of lower utilization concerns, inflation headwinds, and a reset in medtech sector valuations. Analyst Commentary Recent research coverage on Intuitive Surgical shows a clear reset in expectations, but it also highlights that some bullish analysts still see meaningful long term potential in the stock, even as they factor in lower utilization and inflation pressures across medtech.내러티브 업데이트 • Jun 23
ISRG: Sector Reset And Recalls Will Temper Strong Utilization Outlook
Intuitive Surgical's internal fair value estimate has been revised slightly lower to about $413 from roughly $430, as analysts reflect a sector wide reset in price targets tied to lower procedure utilization expectations and tighter assumptions around future medical technology margins. Analyst Commentary Recent Street research around Intuitive Surgical points to a more cautious tone, even from generally constructive voices.분석 기사 • Jun 19
Intuitive Surgical (ISRG) Stock Could Be 23.6% Undervalued After Q1 da Vinci 5 Demand
Intuitive Surgical (ISRG) is back in focus after Q1 2026 data showed 431 da Vinci systems placed, a 17% year over year increase, with upgrades to the da Vinci 5 and higher leasing activity shaping hospital demand. See our latest analysis for Intuitive Surgical. Despite the Q1 2026 da Vinci 5 upgrade cycle and stronger leasing uptake, Intuitive Surgical’s short term share price momentum has softened, with the share price down 27.62% year to date but a 5 year total shareholder return of 34.91%...내러티브 업데이트 • Jun 08
ISRG: Future Returns Will Depend On Procedure Utilization Outpacing Sector Rotation Headwinds
Intuitive Surgical's updated analyst price target has moved lower in line with a reset of fair value from $611.82 to $565.25, as analysts factor in a sector wide pullback in medtech valuations, slightly softer revenue growth assumptions, modestly adjusted discount rates, and a revised future P/E of 53.19 while still citing company specific earnings leverage and product positioning in their broader rationale. Analyst Commentary Recent research on Intuitive Surgical highlights a mix of optimism on long term growth potential and caution around sector specific headwinds and valuation reset.내러티브 업데이트 • May 25
ISRG: Medtech Reset And Recalls Will Shape Future Risk Reward Balance
Intuitive Surgical's updated analyst price target edges down by about $3 to $430.05, as analysts factor in a slightly lower P/E multiple and modest tweaks to growth and margin assumptions in light of recent sector wide medtech valuation resets. Analyst Commentary Recent Street research around Intuitive Surgical has tilted more cautious, with several bearish analysts cutting price targets to reflect what they describe as a reset in medtech valuations, a slower year for product launches, and broader worries about healthcare utilization.내러티브 업데이트 • May 04
ISRG: Policy Shifts And Platform Adoption Will Shape Balanced Risk Reward Profile
Analysts have trimmed the fair value estimate for Intuitive Surgical by about $8 to $433. This reflects a mix of reduced revenue growth assumptions, slightly different discounting and modestly lower future P/E expectations after a series of both price target cuts and upgrades across the Street.내러티브 업데이트 • Apr 20
ISRG: Future Policy Shifts And Platform Adoption Will Shape Premium Multiple
Analysts have trimmed the price target for Intuitive Surgical by about $16 to reflect a slightly higher discount rate and lower assumed future P/E multiple, while maintaining expectations for double digit revenue growth and resilient profit margins supported by a mix of recent target cuts and upgrades across the Street. Analyst Commentary Recent Street research on Intuitive Surgical shows a mix of trimmed price targets and a few upgrades, with most of the action centered on valuation reset rather than drastic changes to fundamental views.내러티브 업데이트 • Apr 05
ISRG: Procedure Expansion And Sector Recovery Will Drive 2026 Upside
Analysts have adjusted Intuitive Surgical's price targets in a mixed but generally constructive way, with revisions ranging from cuts at UBS to $550 and $570 to higher targets at firms like Goldman Sachs at $714 and Bernstein at $740. These changes reflect updated views on growth, margins, and the valuation framework around a future P/E near 65.5x.내러티브 업데이트 • Mar 22
ISRG: Future Platform Adoption And Policy Shifts Will Shape Premium Multiple Sustainability
Intuitive Surgical's updated analyst price target edges lower to $457.50 from $464.58, as analysts balance slightly firmer revenue growth and profit margin assumptions with a modestly lower forward P/E multiple after a mix of recent target cuts and upgrades across the Street. Analyst Commentary Recent research updates on Intuitive Surgical show a mixed backdrop, with several firms trimming price targets even as others reiterate or lift their views.내러티브 업데이트 • Mar 08
ISRG: Future Platform Adoption And Policy Shifts Will Test Premium Multiple Assumptions
The analyst price target for Intuitive Surgical has been trimmed slightly, with modest shifts in fair value and discount rate inputs as analysts balance lower targets from firms like UBS and Citi against higher targets tied to Dv5 driven growth assumptions and sector recovery themes cited by other firms. Analyst Commentary Recent research on Intuitive Surgical shows a split tape, with some firms lifting targets on the back of Dv5 related growth assumptions and sector recovery themes, while others trim targets and stress execution and valuation risks.
새로운 내러티브 • Feb 28
ISRG Riding the Lightning
I have followed ISRG since 2003 when it was brought to the investing club I had just joined. I tried to analyze ISRG with the BetterInvesting SSG methodology that I had been introduced to and I could not get it in the buy zone.내러티브 업데이트 • Feb 22
ISRG: Future Returns Will Hinge On Procedure Utilization Versus Sector Rotation Risk
We have raised our Intuitive Surgical fair value estimate by about $15 to $611.82 per share, as analysts factor in slightly higher revenue growth expectations tied to the Dv5 rollout and sector recovery, partly offset by modestly lower margin assumptions. Analyst Commentary Recent Street research around Intuitive Surgical reflects a mix of optimism about growth drivers such as the Dv5 rollout and capital spending trends, alongside more cautious views on valuation and policy risk.내러티브 업데이트 • Feb 07
ISRG: Future Procedure And Platform Execution Will Test Premium Multiple Assumptions
Analysts nudged their price targets higher on Intuitive Surgical, with a modest fair value move to about $468 per share. They recalibrated assumptions around slightly lower revenue growth, higher profit margins, and a somewhat lower future P/E multiple, following a mix of recent target hikes and trims across the Street.내러티브 업데이트 • Jan 24
ISRG: Procedure Expansion And Sector Rebound Will Support 2026 Upside
Our Intuitive Surgical fair value estimate edges up to $750 from $740 as analysts recalibrate their price targets around updated growth, margin, and P/E assumptions informed by recent research on procedure trends, Dv5 contributions, and sector re-rating. Analyst Commentary Bullish analysts have been revisiting their models around procedure volumes, adoption of the Dv5 platform, and sector valuation resets.
내러티브 업데이트 • Jan 18
ISRG at FV
Update on Valuation (18.10.26) Over the next 5 years I calculate with (actual values from 18.01.26 , price/shr at 533 USD ): Revenue Growth p.a.: 12% (Currently at 14,7%) – we saw the peak of revenue growth with nearly 15%, now even 12% is sporty, but with the „abo like“ revenues from spare parts and software licences, based on a still growing bases of installed systems, realisitc. Profit Margin: 30% (currently at 28,6%) - because spare parts in general have more margin then system sales, and the sales out of spare parts is still growing.내러티브 업데이트 • Jan 10
ISRG: Dv5 Platform Rollout And Rising Procedure Volumes Will Drive 2026 Upside
Analysts have lifted their fair value estimate for Intuitive Surgical to US$740 from US$675, reflecting higher expected profit margins and a somewhat lower future P/E multiple. This change is supported by recent target increases tied to the da Vinci 5 rollout, stronger procedure trends and a more constructive view on healthcare into 2026.내러티브 업데이트 • Dec 24
ISRG: Elevated Expectations Will Expose Premium Pricing To Utilization And Margin Disappointments
Analysts have raised their price targets on Intuitive Surgical by roughly $50-$60 per share, citing stronger than expected Q3 revenue and EPS growth, improving profitability despite tariff and mix headwinds, and encouraging trends in system utilization that support a higher fair value of about $468 per share, even as valuation remains a key consideration. Analyst Commentary Recent Street research on Intuitive Surgical reflects a mix of optimism on the company’s operational momentum and caution around valuation and risk-reward.내러티브 업데이트 • Dec 10
ISRG: Future Returns Will Depend On Utilization Strength Versus Sector Volatility
Analysts nudged their average price target on Intuitive Surgical higher by about $3 to roughly $596, citing stronger than expected Q3 profitability, robust demand, and encouraging utilization trends that more than offset lingering concerns about valuation and sector volatility. Analyst Commentary Analyst reactions to the quarter highlight a mix of optimism around execution and utilization trends alongside lingering concerns about valuation and sector sentiment.내러티브 업데이트 • Nov 26
ISRG: Future Direction Will Balance Demand Strength Against Persistent Sector Volatility
Analysts modestly raised their price targets for Intuitive Surgical, with recent updates clustering in the $525 to $603 range. They cited stronger-than-expected quarterly results and robust demand supporting profitability, despite ongoing sector volatility.내러티브 업데이트 • Nov 12
ISRG: Future Performance Will Depend On Execution Amid Competitive Pressures
The consensus analyst price target for Intuitive Surgical saw a modest revision, decreasing slightly by $1 to $592.96. Analysts cited solid Q3 performance, ongoing profitability, and mixed expectations around future risks and valuation.내러티브 업데이트 • Oct 29
Rising Demand And Cost Pressures Will Shape Robotic Surgery Outlook
The analyst price target for Intuitive Surgical has been raised from $573.55 to $594.29. Analysts cite strong third-quarter earnings, improving profit margins, and robust demand, despite ongoing pressures and competitive risks.내러티브 업데이트 • Oct 14
Emerging Markets Will Expand Robotic-Assisted Surgery Adoption
Analysts have slightly lowered their fair value estimate for Intuitive Surgical to $573.55 from $582.10. They cite mixed views on sales momentum and margin sustainability, despite ongoing strength in fundamentals and recent earnings.분석 기사 • Sep 09
The Returns At Intuitive Surgical (NASDAQ:ISRG) Aren't Growing
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...Seeking Alpha • Apr 18
Intuitive Surgical: Too Many Rain Clouds Coming
Summary Intuitive Surgical dominates the growing robotic surgery market with a 60% share, but faces rising competition from Medtronic and Johnson & Johnson. Intuitive Surgical's high valuation (P/E ratio of 60x) makes it less attractive for new investors. The company boasts high margins, no debt, and strong revenue growth, but faces short-term challenges like import tariffs and competitive pressures. While ISRG is fundamentally strong, I recommend waiting for a more attractive entry point due to current high valuations and market risks. Read the full article on Seeking AlphaSeeking Alpha • Apr 11
Intuitive Surgical: Premium Valuation Meets Mounting Headwinds (Downgrade)
Summary Intuitive Surgical stock outperformed the S&P 500 since September 2024, with Q4 revenue growing 25% year-over-year to $2.41 billion. The installed base of da Vinci surgical systems grew 15% to 9,902 units, with recurring revenue constituting 84% of total revenue. Management forecasts procedure growth slowing from 17% to 13-16% in 2025, with margin pressure expected due to various factors. Despite strong market position and growth, ISRG trades at multiples over four times its peers and appears considerably overvalued on DCF analysis. Read the full article on Seeking Alpha새로운 내러티브 • Mar 30
From Battle Field to Robotic Surgery
Intuitive Surgical (ISRG) is a pioneer in robotic-assisted surgery, revolutionizing the medical field with its da Vinci surgical system. Founded in 1995, the company has continuously innovated, making새로운 내러티브 • Mar 18
Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth
Increased Adoption of Robotic Surgery:Hospitals and surgical centers continue to adopt Intuitive Surgical’s da Vinci systems as clinical evidence shows improved outcomes and reduced recovery times.ExpSeeking Alpha • Mar 09
Intuitive Surgical: Getting Closed To Its Fair Value
Summary Intuitive Surgical is going through a temporary decrease in margins and returns on capital, but as the investment cycle approaches its end, profitability will increase. The company has been heavily investing in expanding production, AI, machine learning, and augmented reality, but CapEx will decrease in 2025. The CEO owns ~70 times its total yearly compensation, so there is a strong alignment between management and shareholders. While the stock is slightly overvalued, there might be an opportunity soon to buy into this outstanding business. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
Intuitive Surgical: The Robot Is Well-Oiled
Summary Intuitive Surgical, with its Da Vinci robots, enjoys a great competitive position in minimally invasive surgery, driven by $6 billion in R&D and first-mover advantage. The business model, with 84% recurring revenue from instruments, accessories, and services, ensures stable growth and high margins, despite occasional stock volatility. Financially, ISRG boasts zero debt and $8.8 billion in cash, but declining margins and high valuation multiples make current stock prices hard to justify. While ISRG's growth prospects are strong, the current valuation suggests limited returns; thus, I cannot rate it a buy but also not a sell. Read the full article on Seeking AlphaSeeking Alpha • Jan 20
Intuitive Surgical: Second Half 2025 Guidance Is Critical To Maintaining Current Euphoria
Summary Intuitive Surgical's share price surged after the company reported 25% YoY revenue growth in the fourth quarter. Despite macro headwinds, robust procedure volumes, international expansion and new product rollouts continue to support growth. While investors probably should look through the current growth surge, particularly given Intuitive's extreme valuation, near term earnings beats could continue to drive the stock higher. Read the full article on Seeking AlphaSeeking Alpha • Dec 27
Intuitive Surgical: Growing Impressively, But It Appears Overvalued
Summary Intuitive Surgical's da Vinci system shows strong growth and innovation, but current valuation warrants a Hold rating due to potential overvaluation risks. The global robotics market is expanding, driven by aging populations and demand for minimally invasive procedures, benefiting Intuitive Surgical's recurring revenue model. Despite impressive financial metrics and growth, high P/E ratio and EV/Sales suggest caution, with intrinsic value calculations indicating potential overvaluation. Regulatory approvals and AI advancements promise future growth, but economic shocks and competitive threats could impact market share and investor confidence. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
Intuitive Surgical: One Of The Best Business Models In The World, But Not At This Price
Summary Intuitive Surgical's da Vinci systems revolutionize minimally invasive surgery, offering superior precision, dexterity, and visualization, leading to better patient outcomes and efficiency. The business model thrives on recurring revenue from disposable instruments and maintenance, ensuring long-term cash flow predictability and resilience. Despite high valuations, Intuitive Surgical's technological superiority, lack of competition, and robust R&D investment justify its premium market position. Given the current overvaluation, I recommend holding shares and waiting for market corrections before buying, projecting a target price of $495 per share by 2030. Read the full article on Seeking Alpha매출 및 비용 세부 내역
매출 및 비용 세부 내역
Intuitive Surgical가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Jun 26 | 11,034 | 3,139 | 2,492 | 1,415 |
| 31 Mar 26 | 10,582 | 2,979 | 2,435 | 1,358 |
| 31 Dec 25 | 10,065 | 2,856 | 2,385 | 1,312 |
| 30 Sep 25 | 9,612 | 2,747 | 2,289 | 1,254 |
| 30 Jun 25 | 9,145 | 2,608 | 2,248 | 1,210 |
| 31 Mar 25 | 8,715 | 2,476 | 2,212 | 1,177 |
| 31 Dec 24 | 8,352 | 2,323 | 2,140 | 1,145 |
| 30 Sep 24 | 7,867 | 2,243 | 2,095 | 1,111 |
| 30 Jun 24 | 7,573 | 2,094 | 2,036 | 1,074 |
| 31 Mar 24 | 7,319 | 1,988 | 1,975 | 1,038 |
| 31 Dec 23 | 7,124 | 1,798 | 1,964 | 999 |
| 30 Sep 23 | 6,851 | 1,517 | 1,863 | 983 |
| 30 Jun 23 | 6,665 | 1,425 | 1,847 | 951 |
| 31 Mar 23 | 6,431 | 1,312 | 1,801 | 913 |
| 31 Dec 22 | 6,222 | 1,322 | 1,712 | 879 |
| 30 Sep 22 | 6,118 | 1,378 | 1,673 | 818 |
| 30 Jun 22 | 5,964 | 1,435 | 1,600 | 767 |
| 31 Mar 22 | 5,906 | 1,644 | 1,532 | 722 |
| 31 Dec 21 | 5,710 | 1,705 | 1,467 | 671 |
| 30 Sep 21 | 5,489 | 1,689 | 1,370 | 637 |
| 30 Jun 21 | 5,163 | 1,623 | 1,305 | 627 |
| 31 Mar 21 | 4,551 | 1,173 | 1,234 | 608 |
| 31 Dec 20 | 4,358 | 1,061 | 1,216 | 595 |
| 30 Sep 20 | 4,307 | 1,053 | 1,227 | 602 |
| 30 Jun 20 | 4,358 | 1,136 | 1,220 | 583 |
| 31 Mar 20 | 4,604 | 1,386 | 1,213 | 560 |
| 31 Dec 19 | 4,479 | 1,379 | 1,178 | 557 |
| 30 Sep 19 | 4,247 | 1,314 | 1,121 | 521 |
| 30 Jun 19 | 4,040 | 1,210 | 1,053 | 492 |
| 31 Mar 19 | 3,850 | 1,147 | 998 | 467 |
| 31 Dec 18 | 3,724 | 1,128 | 941 | 418 |
| 30 Sep 18 | 3,570 | 804 | 876 | 385 |
| 30 Jun 18 | 3,457 | 810 | 847 | 361 |
| 31 Mar 18 | 3,306 | 778 | 820 | 351 |
| 31 Dec 17 | 3,138 | 671 | 811 | 329 |
| 30 Sep 17 | 3,003 | 906 | 762 | 311 |
| 30 Jun 17 | 2,878 | 819 | 736 | 290 |
| 31 Mar 17 | 2,790 | 780 | 712 | 260 |
| 31 Dec 16 | 2,707 | 738 | 692 | 240 |
| 30 Sep 16 | 2,619 | 722 | 666 | 223 |
| 30 Jun 16 | 2,522 | 678 | 653 | 212 |
| 31 Mar 16 | 2,434 | 628 | 643 | 206 |
| 31 Dec 15 | 2,367 | 589 | 627 | 197 |
| 30 Sep 15 | 2,285 | 546 | 621 | 192 |
양질의 수익: ISRG는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: ISRG의 현재 순 이익률 (28.4%)은 지난해 (28.5%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: ISRG의 수익은 지난 5년 동안 연평균 16.7% 증가했습니다.
성장 가속화: 지난 1년간 ISRG 의 수익 증가율(20.4%)은 연간 평균(16.7%)을 초과합니다.
수익 대 산업: ISRG의 지난 1년 수익 증가율(20.4%)은 Medical Equipment 업계의 13.6%를 상회했습니다.
자기자본이익률
높은 ROE: ISRG의 자본 수익률(17.3%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/17 04:04 |
| 종가 | 2026/08/17 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Intuitive Surgical, Inc.는 54명의 분석가가 다루고 있습니다. 이 중 32명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| null null | Argus Research Company |
| David Rescott | Baird |